Utilizing Structures of CYP2D6 and BACE1 Complexes To Reduce Risk of Drug–Drug Interactions with a Novel Series of Centrally Efficacious BACE1 Inhibitors
Journal Article
·
· Journal of Medicinal Chemistry
more »
- Pfizer Worldwide Research and Development, Cambridge, MA (United States). Neuroscience Worldwide Medicinal Chemistry
- Scripps Research Inst., La Jolla, CA (United States)
- Pfizer Worldwide Research and Development, Cambridge, MA (United States). Neuroscience Research Unit
- Pfizer Worldwide Research and Development, Cambridge, MA (United States). Center of Chemistry Innovation and Excellence
- Pfizer Worldwide Research and Development, Cambridge, MA (United States). Pharmacokinetics, Dynamics, and Metabolism, Pharmaceutical Sciences
- Pfizer Worldwide Research and Development, Groton, CT (United States). Neuroscience Worldwide Medicinal Chemistry
- WuXi AppTec, Shanghai (China)
In recent years, the first generation of β-secretase (BACE1) inhibitors advanced into clinical development for the treatment of Alzheimer’s disease (AD). However, the alignment of drug-like properties and selectivity remains a major challenge. Here in this paper, we describe the discovery of a novel class of potent, low clearance, CNS penetrant BACE1 inhibitors represented by thioamidine 5. Further profiling suggested that a high fraction of the metabolism (>95%) was due to CYP2D6, increasing the potential risk for victim-based drug–drug interactions (DDI) and variable exposure in the clinic due to the polymorphic nature of this enzyme. To guide future design, we solved crystal structures of CYP2D6 complexes with substrate 5 and its corresponding metabolic product pyrazole 6, which provided insight into the binding mode and movements between substrate/inhibitor complexes. Guided by the BACE1 and CYP2D6 crystal structures, we designed and synthesized analogues with reduced risk for DDI, central efficacy, and improved hERG therapeutic margins.
- Research Organization:
- Argonne National Lab. (ANL), Argonne, IL (United States). Advanced Photon Source (APS)
- Sponsoring Organization:
- National Institutes of Health (NIH); USDOE Office of Science (SC), Basic Energy Sciences (BES) (SC-22)
- Grant/Contract Number:
- AC02-06CH11357
- OSTI ID:
- 1183594
- Journal Information:
- Journal of Medicinal Chemistry, Journal Name: Journal of Medicinal Chemistry Journal Issue: 7 Vol. 58; ISSN 0022-2623
- Publisher:
- American Chemical Society (ACS)Copyright Statement
- Country of Publication:
- United States
- Language:
- ENGLISH
Similar Records
Aminomethyl-Derived Beta Secretase (BACE1) Inhibitors: Engaging Gly230 without an Anilide Functionality
How Informative Are Drug‐Drug Interactions of Gene‐Drug Interactions?
Systematic and quantitative assessment of the effect of chronic kidney disease on CYP2D6 and CYP3A4/5
Journal Article
·
Tue Dec 20 00:00:00 UTC 2016
· Journal of Medicinal Chemistry
·
OSTI ID:1506536
How Informative Are Drug‐Drug Interactions of Gene‐Drug Interactions?
Journal Article
·
Tue Apr 26 00:00:00 UTC 2016
· Journal of Clinical Pharmacology
·
OSTI ID:1400958
Systematic and quantitative assessment of the effect of chronic kidney disease on CYP2D6 and CYP3A4/5
Journal Article
·
Mon Mar 07 00:00:00 UTC 2016
· Clinical Pharmacology and Therapeutics
·
OSTI ID:1623522